… pregnancy. Into this mix one must add the scarcity of data on the safety of drugs during
conception, pregnancy, and lactation, because pregnant … of biological therapy during pregnancy …

… The aim of this article is to critically review available data regarding the safety of
immunomodulators and biological therapies during pregnancy and breast-feeding in women with …

… It’s conceivable that in the next 5 years, the evidences about the safety of biologic agents
during pregnancy will grow and we will witness to a great expansion of the use of these new …

… on the risk of pediatric complications of anti-TNF exposure during pregnancy. No adverse …
At birth cord blood of children exposed to biological should be drawn to measure biological …

… Certain NSAIDs are considered compatible with breastfeeding by the American Academy
of Pediatrics … In terms of biologic therapy, most information available is for TNFα inhibitor …

… pregnant women were exposed to anti-TNF agents . The pregnant women were exposed to
the biological therapies … were exposed to biological therapies during pregnancy, highest rate …

… of biologic agents use in pediatric rheumatology. 433 children with different types of juvenile
arthritis (JA) were treated with biologic … that differentiated biological therapy unlike classic …

… of biological therapies during pregnancy. Furthermore, since most recent data suggest that
anti-B-cell drugs have an effective B-cell depleting ability in both the mother and offspring, …

… of pediatric IBD. The role of Infliximab and Adalimumab in the management of pediatric IBD
has … , efficacy, and safety of biological therapy in pediatric IBD patients, evaluating all articles …

… IBD, compares the outcome in pregnant IBD mothers exposed to thiopurines and anti-TNF-α
agents. It has reinforced the claim that biologic therapy in pregnant IBD patients did not lead …